

DOCKET NO.: 283726US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
Antoni TORRENS JOVER, et al.

GROUP: 1625

SERIAL NO: 10/565,979

EXAMINER: O'DELL, DAVID K.

FILED: November 5, 2007

FOR: 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE
DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5
(NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R. 1.48

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

It is requested that the Inventorship of the above-identified application be corrected under the provisions of 37 C.F.R. 1.48 to add Helmut Buschmann. Included with this request is

(1) A statement from Helmut Buschmann that the error in inventorship occurred without deceptive intention on his or her part;

(2) A substitute oath or declaration by the corrected inventors;


(3) The processing fee set forth in § 1.17(i); and

(5) A written consent of the assignee for this change.

Expedited handling and confirmation of this change is requested.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Daniel J. Pereira
Registration No. 45,518

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 08/07)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
Antoni TORRENS JOVER, et al.

GROUP: 1625

SERIAL NO: 10/565,979

EXAMINER: O'DELL, DAVID K.

FILED: November 5, 2007

FOR: 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE
DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5
(NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

ASSIGNEE CONSENT FOR A CHANGE OF INVENTORSHIP UNDER 37 C.F.R. 1.48

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

I, Eduard Valenti, state that:

(1) I understand that HELMUT BUSCHAMNN was inadvertently and without deceptive intent omitted as an inventor of the above-identified application and that a request to correct this omission will be submitted with this statement;


(2) An assignment was granted by the originally named inventors, Laboratorios del Dr. Esteve, S.A., of Spain;

(3) I am authorized to make these statements on behalf of the assignee of this application;

(4) the assignee, LABORATORIOS DEL DR. ESTEVE, S.A. consents to this change of inventorship; and

(5) I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.



Signature

Eduard VALENTÍ VALL
Legal Representative

Name

2nd September 2010

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
Antoni TORRENS JOVER, et al.

GROUP: 1625

SERIAL NO: 10/565,979

EXAMINER: O'DELL, DAVID K.

FILED: November 5, 2007

FOR: 2'-4(PHENYLAMINO)-PIPERIDIN-1-YL-N-PHENYL-ACETAMINE
DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5
(NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R.1.48

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313


SIR:

I, Helmut Buschmann, state that

- (1) I am an inventor of the above-identified application because I conceived of at least a part of the invention claimed in the application;
- (2) I was inadvertently omitted as an inventor of the above-identified application;
- (3) The error in inventorship occurred without deceptive intention on my part; and
- (4) I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

2nd September 2010

Date



Helmut Buschmann